Serum Folate, MTHFR C677T Polymorphism and Esophageal Squamous Cell Carcinoma Risk

This study examined associations between MTHFR C677T polymorphism and serum folate concentrations with the risk of esophageal precancerous lesions （EPL） and esophageal squamous cell carcinoma （ESCC）. The highest quartile of serum folate concentration significantly decreased the risk of ESCC compared with the lowest quartile （0R=0.11; 95% CI, 0.04-0.33; P〈0.05）. MTHFR 677 C〉T polymorphism was associated with the risk of ESCC by using chi-square tests （P〈0.05）. For the CT genotype, the risk of ESCC significantly increased in study participants with low serum folate concentrations （〈26.92μg/L） compared with participants with high serum folate concentrations （〉26.92 μg/L） by using multinomial logistic regression models. The MTHFR genotype may further modify associations between serum folate concentrations and the risk of ESCC, but it was not significantly associated with the risk of EPL.

Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid-and long-term prediction of hepatocellular carcinoma among cirrhotic patients

BACKGROUND The combination of alpha-fetoprotein(AFP)and squamous cell carcinoma antigen immunocomplex(SCCA-IgM)have been proposed for its use in the screening of hepatocellular carcinoma(HCC).Current screening programs for all cirrhotic patients are controversial and a personalized screening is an unmet need in the precision medicine era.AIM To determine the role of the combination of SCCA-IgM and AFP in predicting mid-and long-term appearance of HCC.METHODS Two-hundred and three cirrhotic patients(Child A 74.9%,B 21.2%,C 3.9%)were followed-up prospectively every six months to screen HCC by ultrasound and AFP according to European Association for the Study of the Liver guidelines.The estimation cohort was recruited in Italy(30.5%;62/203)and validation cohort from Spain(69.5%;141/203).Patients underwent to evaluate SCCA-IgM by enzyme-linked immunosorbent assay(Hepa-IC,Xeptagen,Italy)and AFP levels at baseline.Patients were followed-up for 60 mo,being censored at the time of the appearance of HCC.RESULTS There were 10.8%and 23.1%of HCC development at two-and five-years followup.Patients with HCC showed higher levels of SCCA-IgM than those without it(425.72±568.33 AU/mL vs 195.93±188.40 AU/mL,P=0.009)during the fiveyear follow-up.In multivariate analysis,after adjusting by age,sex,aspartate transaminase and Child-Pugh,the following factors were independently associated with HCC:SCCA-IgM[Hazard ratio(HR)=1.001,95%CI:1.000-1.002;P=0.003],AFP(HR=1.028,95%CI:1.009-1.046;P=0.003)and creatinine(HR=1.56495%CI:1.151-2.124;P=0.004).The log-rank test of the combination resulted in 7.488(P=0.024)in estimation cohort and 11.061(P=0.004)in the validation cohort,and a 100%of correctly classified rate identifying a low-risk group in both cohorts in the two-year follow-up.CONCLUSION We have constructed a predictive model based on the combination of SCCA-IgM and AFP that provides a new HCC screening method,which could be followed by tailored HCC surveillance for individual patients,especially for those cirrhotic patients belonging to the subgroup identified as low-risk of HCC development.

Clinical applications of squamous cell carcinoma antigenimmunoglobulins M to monitor chronic hepatitis C

Hepatitis C virus(HCV) is the main cause of chronic liver disease and cirrhosis in Western countries. Over time, the majority of cirrhotic patients develop hepatocellular carcinoma(HCC), one of the most common fatal cancers worldwide- fourth for incidence rate. A high public health priority need is the development of biomarkers to screen for liver disease progression and for early diagnosis of HCC development, particularly in the high risk population represented by HCV-positive patients with cirrhosis. Several studies have shown that serological determination of a novel biomarker, squamous cell carcinoma antigen-immunoglobulins M(SCCA-Ig M), might be useful to identify patients with progressive liver disease. In the initial part of this review we summarize the main clinical studies that have investigated this new circulating biomarker on HCV-infected patients, providing evidence that in chronic hepatitis C SCCA-Ig M may be used to monitor progression of liver disease, and also to assess the virological response to antiviral treatment. In the last part of this review we address other, not less important, clinical applications of this biomarker in hepatology.

High expression of squamous cell carcinoma antigen in poorly differentiated adenocarcinoma of the stomach: A case report

BACKGROUND Squamous cell carcinoma antigen(SCCA)is regarded as a specific indicator of epithelial malignancies and is widely used in the diagnosis of squamous cell carcinoma(SCC).However,the expression of SCCA in gastric adenocarcinoma has not been studied in detail.CASE SUMMARY A 52-year-old man was admitted to our hospital for a 2.5 cm x 2.5 cm ulcer at the antrum-body junction with dull pain and fullness in the upper abdomen for 2 mo.His pre-surgery serological testing results showed 0.51 ng/mL SCCA(reference interval,<1.5 ng/mL)and 9.9 ng/mL carcinoembryonic antigen(reference range,<4.7 ng/mL).He underwent radical distal gastrectomy and Roux-en Y anastomosis and was diagnosed with poorly differentiated mucinous adenocarcinoma(Lauren classification:Diffuse)by pathological examination of the resected lesion.Immunohistochemistry showed that SCCA was highly expressed in the cytoplasm of cancer cells.After surgery,the patient received an S-1 adjuvant chemotherapy regimen for six cycles containing tegafur,gimeracil,and oteracil potassium.He showed no sign of recurrence or metastasis within 24-mo follow-up.CONCLUSION This is a frontal report of SCCA overexpression in poorly differentiated adenocarcinoma of the stomach.

High level of preoperative serum fibrinogen is a predictor of poor prognosis in patients with esophageal squamous cell carcinoma

Objective This study aimed to elucidate the association between the level of preoperative serum fibrinogen(PSF)and the prognosis of patients with esophageal squamous cell carcinoma(ESCC).Methods From January 2010 to December 2016,all patients diagnosed with ESCC who underwent surgery in Qingdao Municipal Hospital were analyzed retrospectively.Moreover,the fibrinogen levels of all patients were assessed before surgery,and hyperfibrinogenemia was diagnosed when the fibrinogen level was≥4.0 g/L.The impact of PSF on disease-free survival(DFS)and overall survival(OS)was analyzed using the log-rank method and Cox proportional hazards regression model.P value less than 0.05 was considered statistically significant.Results A total of 336 patients were finally analyzed,and approximately 102 patients(30.36%)were diagnosed with hyperfibrinogenemia before surgery.Hyperfibrinogenemia was associated with older age(≥70 years)(P=0.012),advanced pathological T stage(P=0.003),and lymph node involvement(P=0.024).Univariate analysis showed that patients with hyperfibrinogenemia had shorter DFS(1.96 years vs.3.64 years,P=0.001)and OS(2.27 years vs.4.15 years,P<0.001)than patients without hyperfibrinogenemia.Multivariate analysis confirmed that PSF was an independent factor affecting DFS(risk ratio[RR]:1.35,95%confidence interval[CI]:1.02-1.79,P=0.038)and OS(RR:1.37,95%CI:1.03-1.83,P=0.034)in patients with ESCC.Conclusion For patients with operable ESCC,hyperfibrinogenemia had poor prognosis.Moreover,PSF is an independent prognostic factor for operable ESCC.

Impact of Preoperative Serum Tumor Markers in Patients with Lung Squamous Cell Carcinoma

Background: Several previous researchers have investigated the prognostic value of serum tumor markers, especially carcinoembryonic antigen (CEA). Only a limited number of studies reported the usefulness of serum tumor markers for lung squamous cell carcinoma (SQ). We aimed to examine the significance of serum tumor markers for lung SQ. Methods: Eighty-five lung SQ patients who underwent surgery and followed more than 5-year were included. The ratios of 5-year survivors to all patients in groups with several clinicopathologic factors, including tumor markers, were compared. We also compared the clinicopathologic factors between central type and peripheral type SQ. Results: The majority of patients were male gender and current/ former smokers. Age, pN status, cytokeratin-19 fragment (CYFRA 21-1), squamous cell carcinoma antigen (SCC), and comorbid interstitial pneumonia (IP) were associated with the ratio of 5-year survivors significantly. When patients were compared based on tumor location, high p-stage and CYFRA 21-1 were related to central type SQ. Conclusion: Both SCC and CYFRA 21-1 appeared to be useful prognostic markers for patients with lung SQ. Furthermore, CYFRA 21-1 was related to central type SQ.

Salivary and Serum IgA Evaluation of Patients with Oro-Facial Squamous Cell Carcinoma

Objective: To evaluate salivary and serum levels of Immunoglobulin A (IgA) in patients with oro-facial squamous cell carcinoma. Methods: This is a cross sectional study. Patients with oro-facial squamous cell carcinoma attending the Oral Pathology and Radiotherapy clinics of the University College Hospital, Ibadan, Nigeria were included. Seventy subjects comprising 22 patients with untreated OSCC, 18 patients with OSCC receiving treatment and 30 healthy, age and gender matched individuals were included. Serum and salivary samples from the participants were analysed for IgA levels using ELISA technique. Results: The mean value of serum IgA in OSCC patients receiving treatment was significantly lower compared with healthy controls (p = 0.03), while no significant difference was observed comparing untreated OSCC patients with treated and healthy controls. The salivary IgA levels did not show any significant difference between the three groups (p = 0.73). Also, there was no correlation between serum and salivary levels of IgA among the subjects. Conclusions: Serum IgA appeared to be better index than salivary IgA levels in monitoring response to treatment in patients with oro-facial carcinoma.

Differentially Expressed Serum Protein Profiling in Esophageal Squamous Cell Carcinoma Patients with Different Chinese Medicine Syndromes

Objective:Esophageal carcinoma is the eighth most common malignant tumor and ranked the sixth cause of death in the worldwide careinoma.To find out effective serum markers for early diagnosis and targeted treatment is important to improve esophageal carcinoma survival rate.The aim of this study was to screen differ-entially expressed serum protein profiling in esophageal squamous cell careinoma(ESCC)patients with differ-ent Chinese medicine syndrome and establish ESCC syndrome diagnosis model,to explore the signifcance of ESCC serum differential protein in traditional Chinese medicine(TCM)syndrome diagnosis and provide exper-imental and theoretical basis for the diagnosis,clinical treatment of ESCC.Methods:Serum specimens of 80 ES-CC patients with different syndrome and 20 healthy people were selected according to distribution of their sex and age.Magnetic beads based weak cation exchange combined w ith matrix-assist ed laser desorption/ionization time-of-flight mass spectrometry prot eomic technology and Autoflex Analysis and ClinProTools software were applied to screen differentially expressed serum protein profiling.Then establishing each syndrome group diag-nosis model and verifying with new samples to evaluate the diagnosis value of each syndrome group diagnosis model.Results:18 significantly differential expression protein peaks were screened between the whole ESCC patients sera and the healthy control group.Compared with normal control group,among which,ten were signif-cant down-regulation with m/z values of4210,4267,4054,4248,2106,4091,2991,5337,3952,822,and eight were significant up-regulation with m/z values of 2900,2883,1467,1617,2862,2600,895,811.There were 16,12,11,15 differentially expressed protein peaks in phlegm and qi stagnat ion syndrome(Group P),fluid insufficiency and heat agglomeration syndrome(Group F),blood stasis syndrome(Group B),qi and yang deficiency syndrome(Group Q),respectively.Protein with m/z of4210,4091,4054 and 5337 presen-ted obviously low expression in all syndrome groups,while protein with m/z of2883,1617 presented obvious-y high expression.Protein with m/z of 4644 is an obvious and significative biomarker in the comparison of dif-ferent syndrome of ESCC.Establishing ESCC each syndrome serum different ial protein profiling diagnosis mod-el showed that the specificity and veracity in four syndrome groups were all≥80.00%.Conclusion:Our study achieved differentially expressed protein profiling in ESCC patients with different TCM syndromes,established relatively high sensitivity and specificity of different syndrome of ESCC serum differential protein profiling diag-nosis model,which implied the screened syndrome related serum differential expression protein in TCM syn-drome differentiation and diagnosis had great clinical meaning,could be the assistant diagnosis biomarker of ESCC.

Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma

AIM： To evaluate the diagnostic values of serum autoan tibodies against matrix metalloproteinase-7 （MMP-7） in patients with esophageal squamous cell carcinoma （ESCC）. METHODS： The MMP-7 cDNA was cloned from ESCC tissues, and MMP-7 was expressed and purified from a prokaryotic system. MMP-7 autoanUbodies were then measured in sera from 50 patients with primary ESCC and 58 risk-matched controls, using a reverse capture enzyme-linked immunosorbent assay （ELISA） in which autoantibodies to MMP-7 bound to the purified MMP-7 proteins. In addition, MMP-7 autoantibody levels in sera from 38 gastric cancer patients and from control serum samples were also tested. RESULTS： The optimum conditions for recombinant MMP-7 protein expression were determined as 0.04 mmol/L Isopropyl-13-D-Thiogalactopyranoside （IPTG）induction at 37℃ for four hours. The levels of serum autoantibodies against MMP-7 were significantly higher in patients with ESCC than in the matched-control samples （OD450 = 1.69 ±0.08 vs OD450 = 1.55 ± 0.10, P 〈 0.001）. The area under the receiver operating character- istic （ROC） curve was 0.87. The sensitivity and specificity for detection of ESCC were 78.0% and 81.0%, respectively, when the OD450 value was greater than 1.65. Although the levels of autoantibodies against MMP-7 were also significantly higher in patients with gastric cancer compared to control samples （OD450 = 1.62± 0.06 vs OD450 = 1.55±0.10, P 〈 0.001）, the diagnostic accuracy was less significant than in ESCC patients. The area of ROC curve was 0.75, whereas the sensitivity and specificity were 60.5% and 71.7%, respectively, when the cut-off value of OD450 was set at 1.60. CONCLUSION： Serum autoantibody levels of MMP-7 may be a good diagnostic biomarker for esophageal squamous cell carcinoma,

Identification of interleukin-6 (IL-6) and squamous cell carcinoma (SCC) as amniotic fluid-specific markers

Objective: To determine if an amniotic fluid (AF)-specific marker is present and if its concentration changes with the presence of labor. Study Design: Twenty-six healthy women who gave birth to healthy newborns at term during the period from July 2009 to January 2010 were included in the study. Six candidate markers were assessed by commercially available ELISA kits: interleukin (IL)-6, squamous cell carcinoma (SCC) antigen, insulin-like growth factor (IGFBP)-1, osteopontin (OPN), CA125, and sialyl Tn (STN). Results: The AF/maternal serum (MS) measurement based on IL-6 or SCC has proved to be superior to IGFBP-1, CA125, OPN and STN. Women with spontaneous labor at term had significantly higher IL-6 and IGFBP-1 concentrations in AF compared with those without labor. No significant differences were observed in the AF concentrations of SCC, OPN, CA125 and STN between women with labor and those not in labor. Conclusion: Our observation of IL-6 and SCC in AF may open a new area of research to assess their usefulness as biological markers of obstetrical disorders.

宫颈癌患者血清SCC-Ag、NLR水平与临床病理特征及预后关系

目的:探讨宫颈癌患者血清鳞状细胞癌抗原(SCC-Ag)、中性粒细胞与淋巴细胞比值(NLR)与临床病理特征及预后关系。方法:纳入2018年1月-2023年1月本院收治的108例宫颈癌患者为宫颈癌组,宫颈上皮内瘤病变(CIN)患者108例为CIN组,健康体检健康女性108例为对照组。比较3组血清SCC-Ag、NLR水平,分析宫颈癌组血清SCC-Ag、NLR水平与临床病理特征及与预后关系。结果:血清SCC-Ag、NLR水平,宫颈癌组(7.35±1.76、4.65±1.06)、CIN组(2.06±0.53、3.41±0.89)、对照组(0.54±0.12、1.53±0.34)依次降低(P<0.05)。宫颈癌患者血清SCC-Ag、NLR水平与病理类型、FIGO分期、病理分级、肌层浸润深度和盆腔淋巴结转移有关(P<0.05)。Kaplan-Meier显示,SCC-Ag、NLR高表达组总生存率、无病生存率均低于SCC-Ag、NLR低表达组,SCC-Ag高表达+NLR高表达组总生存率、无病生存率最低(均P<0.05)。结论:宫颈癌患者血清SCC-Ag、NLR水平与病理类型、FIGO分期、病理分级和肌层浸润深度等有关,且SCC-Ag、NLR水平越高患者预后越差。

血清SCC-Ag、HE4、SMAD4水平与宫颈癌放化疗敏感性的相关性分析

目的分析血清鳞状细胞癌相关抗原(SCC-Ag)、人附睾分泌蛋白4(HE4)、SMAD4水平与宫颈癌放化疗敏感性的相关性。方法选取接受放化疗治疗的宫颈癌患者74例为研究对象,根据放化疗敏感性分为抵抗组和敏感组,分别有48例和26例。检测患者治疗前后血清SCC-Ag、HE4及SMAD4 mRNA水平,分析治疗前血清SCC-Ag、HE4、SMAD4水平与超声参数的相关性。绘制受试者工作特征曲线(ROC)描述治疗前SCC-Ag、HE4及SMAD4 mRNA水平对放化疗敏感性的预测价值。结果治疗后2组患者血清SCC-Ag、HE4水平较治疗前降低,SMAD4 mRNA水平较治疗前升高(P<0.05);且敏感组患者治疗前、后SCC-Ag、HE4水平均低于抵抗组,SMAD4 mRNA水平均高于抵抗组(P<0.05)。治疗前血清SCC-Ag、HE4与VI呈正相关(γ=0.518、0.544,P<0.05),SMAD4 mRNA与VI呈负相关(γ=-0.581,P<0.05)。ROC曲线显示,治疗前SCC-Ag、HE4及SMAD4 mRNA联合对放化疗敏感性的预测价值较高,AUC为0.863(95%CI:0.764~0.962)。结论血清SCC-Ag、HE4及SMAD4 mRNA水平与宫颈癌放化疗敏感性密切相关,且三者联合对放化疗敏感性具有较高的预测价值。

Ribonucleotide reductase small subunit M2 promotes the proliferation of esophageal squamous cell carcinoma cells via HuR-mediated mRNA stabilization

Esophageal squamous cell carcinoma(ESCC),a malignancy of the digestive system,is highly prevalent and the primary cause of cancer-related deaths worldwide due to the lack of early diagnostic biomarkers and effective therapeutic targets.Dysregulated ribonucleotide reductase(RNR)expression has been confirmed to be causally linked to tumorigenesis.This study demonstrated that ribonucleotide reductase small subunit M2(RRM2)is significantly upregulated in ESCC tissue and that its expression is negatively correlated with clinical outcomes.Mechanistically,HuR promotes RRM2 mRNA stabilization by binding to the adenine/uridine(AU)-rich elements(AREs)within the 3′UTR,resulting in persistent overexpression of RRM2.Furthermore,bifonazole is identified as an inhibitor of HuR via computational screening and molecular docking analysis.Bifonazole disrupts HuR-ARE interactions by competitively binding to HuR at F65,R97,I103,and R153 residues,resulting in reduced RRM2 expression.Furthermore,bifonazole exhibited antitumor effects on ESCC patient-derived xenograft(PDX)models by decreasing RRM2 expression and the dNTP pool.In summary,this study reveals the interaction network among HuR,RRM2,and bifonazole and demonstrated that bifonazole is a potential therapeutic compound for ESCC through inhibition of the HuR/RRM2 axis.

血清SCC-Ag、CA50、CYFRA21-1水平与上皮性卵巢癌患者临床分期及预后的关系

目的:探讨上皮性卵巢癌(EOC)患者血清鳞状细胞癌抗原(SCC-Ag)、糖链抗原50(CA50)、细胞角蛋白19片段(CYFRA21-1)水平与临床分期及预后的关系。方法:纳入本院2018年6月至2020年10月收治的76例EOC患者为研究对象(EOC组),其中国际妇产科协会(FIGO)Ⅰ期12例、Ⅱ期24例、Ⅲ期19例、Ⅳ期21例。另选取80例体检健康者为对照组。化学发光免疫分析法测定SCC-Ag、CA50、CYFRA21-1水平。患者随访3年,分为预后不良组(死亡患者)30例与预后良好组(存活患者)46例。血清SCC-Ag、CA50、CYFRA21-1水平与临床分期的相关性采用Spearman相关分析;受试者工作特征(ROC)曲线分析血清SCC-Ag、CA50、CYFRA21-1水平对EOC患者预后的预测价值;Kaplan-Meier生存曲线分析血清SCC-Ag、CA50、CYFRA21-1表达与EOC患者预后的关系;多因素Cox回归分析患者预后不良的影响因素。结果:与对照组相比,EOC组血清SCC-Ag、CA50、CYFRA21-1水平显著升高(P<0.001)。随着EOC患者FIGO分期的升高,SCC-Ag、CA50、CYFRA21-1水平依次显著升高(P<0.05)。EOC患者血清SCC-Ag、CA50、CYFRA21-1水平与FIGO分期呈正相关(P<0.05)。预后不良组血清SCC-Ag、CA50、CYFRA21-1水平高于预后良好组(P<0.001)。血清SCC-Ag、CA50、CYFRA21-1水平单独及联合预测EOC患者预后不良的AUC分别为0.868、0.857、0.850、0.954,且三者联合预测优于单独诊断(Z值分别为2.214、2.826、2.831,P<0.05)。SCC-Ag、CA50、CYFRA21-1高表达患者3年生存率分别低于SCC-Ag、CA50、CYFRA21-1低表达者(Log-rankχ^(2)值分别为21.494、21.449、16.727,P<0.001);多因素Cox回归分析显示,SCC-Ag、CA50、CYFRA21-1是EOC患者预后不良的危险因素(P<0.05)。结论:EOC患者血清SCC-Ag、CA50、CYFRA21-1水平升高与临床分期及预后密切相关。

血清CEA、NSE、SCC-Ag和CA125联合检验在非小细胞肺癌中的诊断价值

目的探究血清癌胚抗原(CEA)、神经特异性烯醇化酶(NSE)、鳞癌相关抗原(SCC-Ag)、糖类抗原125(CA125)联合检验在非小细胞肺癌(NSCLC)中的诊断价值。方法选取2021年1月至2024年1月在本院就诊的110例NSCLC患者作为NSCLC组,另选取同期在本院体检的健康志愿者50例作为对照组。比较2组血清CEA、NSE、SCC-Ag以及CA125水平的差异;依据病理T分期将NSCLC组患者分为T1期、T2期、T3期3个不同亚组,依据病理N分期将NSCLC患者分为N0期、N1期、N2期3个不同亚组,比较不同病理T分期、N分期NSCLC患者血清CEA、NSE、SCC-Ag以及CA125水平的差异;并绘制ROC曲线分析上述指标单一及联合在NSCLC诊断中的效能。结果在CEA、NSE、SCC-Ag、CA125水平比较上,NSCLC组均高于对照组(P<0.05)。血清CEA、NSE、SCC-Ag、CA125水平均随NSCLC患者病理T分期的递增而升高(P<0.05),且各分期结果比较差异有统计学意义(P<0.05)。血清CEA、NSE、SCC-Ag、CA125水平均随NSCLC患者病理N分期的递增而升高(P<0.05),且各分期结果比较差异有统计学意义(P<0.05)。CEA、NSE、SCC-Ag、CA125诊断NSCLC的AUC分别为0.869(95%CI为0.827~0.917)、0.873(95%CI为0.812~0.921)、0.854(95%CI为0.789~0.905)、0.826(95%CI为0.758~0.881),4者联合诊断NSCLC的AUC为0.982(95%CI为0.947~0.996),均较CEA、NSE、SCC-Ag、CA125各单一指标效能更高(Z=4.152、4.268、4.663、4.783,P<0.001)。结论血清CEA、NSE、SCC-Ag、CA125与NSCLC病理类型、淋巴结转移数目、EGFR基因型等存在关系,且通过联合检测CEA、NSE、SCC-Ag、CA125水平可有效提高临床诊断NSCLC的效能。

DWI联合血清SCC-Ag宫颈癌术前预测临床分期及术后3年预后价值

目的:评价扩散加权磁共振成像(DWI)联合外周血鳞状细胞癌抗原(SCC-Ag)诊断宫颈癌术前临床分期的效能及预测预后价值。方法:回顾性收集2016年9月-2021年3月本院收治的150例宫颈癌和20例健康体检者(健康组)为研究对象,均接受盆腔DWI检查及外周血SCC-Ag水平检测,宫颈癌患者均接受手术治疗,记录患者术后3年预后并分为预后良好组及预后不佳组,比较两组宫颈癌瘤灶的DWI表观扩散系数(ADC值)及外周血SCC-Ag水平。采用Kappa检验评估DWI影像宫颈癌术前临床分期与临床病理分期的一致性;采用受试者工作特征(ROC)曲线评价ADC值联合SCC-Ag预测宫颈癌患者术后3年预后价值。结果:宫颈癌患者随宫颈癌分期增高ADC值降低、SCC-Ag水平增高(均P<0.05)。150例患者均接受随访,随访时间2.5~7.1年,随访中位数3.0年,33例(22.0%)预后不佳,其ADC值(0.90±0.24)均低于预后良好患者(1.21±0.21),外周血SCC-Ag(11.07±1.72 ng/ml)高于预后良好患者(7.72±1.43 ng/ml)(均P<0.05)。宫颈癌患者病理及DWI联合外周血SCC-Ag诊断宫颈癌术前临床分期的kappa=0.7790(95%CI 0.7185~0.9655,P=0.000),一致性较好。ROC分析,外周血SCC-Ag及DWI的ADC值评估宫颈癌患者3年预后的曲线下面积分别为0.936±0.021、0.948±0.018,ADC值联合外周血SCC-Ag评估预后的曲线下面积(0.956±0.018)最高。结论:DWI联合外周血SCC-Ag在诊断宫颈癌术前临床分期一致性较好,且预测患者术后3年月预后效能较高。

HPV-DNA联合SCC-Ag、CA19-9、AFP检测诊断宫颈癌的临床价值

目的:分析人乳头瘤病毒DNA(HPV-DNA)联合鳞状细胞癌抗原(SCC-Ag)、糖类抗原19-9(CA19-9)及甲胎蛋白(AFP)检测在宫颈癌诊断中的临床价值。方法:回顾性收集2018年3月-2022年3月本院诊治的宫颈癌患者、宫颈良性病变患者各80例临床资料,分别纳入宫颈癌组、良性病变组,同期健康体检女性50例纳入对照组,比较3组以及宫颈癌组不同FIGO分期患者血清SCC-Ag、CA19-9、AFP表达水平及HPV-DNA、SCC-Ag、CA19-9、AFP阳性率,以病理诊断为“金标准”,评价HPV-DNA、SCC-Ag、CA19-9、AFP单独及联合检测对宫颈癌的诊断效能。结果:宫颈癌组血清SCC-Ag、CA19-9、AFP表达水平均高于良性病变组与对照组,HPV-DNA、SCC-Ag、CA19-9、AFP阳性率均高于良性病变组与对照组,且宫颈癌组Ⅲ~Ⅳ期患者血清SCC-Ag、CA19-9、AFP表达水平均高于Ⅰ~Ⅱ期患者,HPV-DNA、CA19-9、AFP阳性率均高于Ⅰ~Ⅱ期患者(均P<0.05);HPV-DNA、SCC-Ag、CA19-9、AFP联合检测诊断宫颈癌的敏感度(96.3%)、准确度(91.8%)均高于各项单独检测,AFP诊断特异度最高达100.0%(P<0.05)。结论:HPV-DNA联合SCC-Ag、CA19-9、AFP检测可提高宫颈癌的诊断效能。

血清HE4、SCC-Ag联合TCT检查诊断宫颈癌价值

目的:探讨血清人附睾上皮分泌蛋白4(HE4)、鳞状细胞癌相关抗原(SCC-Ag)联合宫颈薄层液基细胞学检测(TCT)诊断宫颈癌(CC)价值。方法:收集2021年10月-2023年7月本院病理确诊CC患者40例(CC组)、宫颈良性病变(CBL组,包括宫颈炎、宫颈上皮内瘤变)患者228例为CBL组。对比两组血清HE4、SCC-Ag水平,两组HE4、SCC-Ag、TCT检测CL阳性检出率;根据病理结果分析血清HE4、SCC-Ag水平、TCT诊断CL价值。结果:CC组血清HE4(188.71±39.15 pmol/L)、SCC-Ag(1.81±0.21 ng/ml)水平高于CBL组(73.65±11.52 pmol/L、0.64±0.12 ng/ml)(P<0.05)。TCT、HE4、SCC-Ag诊断CC的灵敏度(82.5%、72.5%、75.0%),特异度(77.6%、87.7%、86.8%),准确度(78.4%、85.5%、85.1%),3项指标联合诊断CC的灵敏度70.0%、特异度93.9%、准确度90.3%,联合检测准确度高于各单独指标检测(P<0.05)。结论:CC患者血清HE4、SCC-Ag水平及TCT检测阳性率均高于CBL患者,3项指标联合诊断准确度提高。

激素替代疗法改善宫颈鳞癌术后患者更年期综合征的有效性和安全性及对其血清SCC-Ag、MMP-9的影响

目的探讨激素替代疗法(HRT)改善宫颈鳞癌术后患者更年期综合征的有效性和安全性及对其血清肿瘤标志物鳞状细胞癌抗原(SCC-Ag)、基质金属蛋白酶-9(MMP-9)的影响。方法回顾性选取2018年4月至2022年5月在保定市第一中心医院行手术治疗的86例宫颈鳞癌患者作为研究对象,按术后治疗方案的不同,分为对照组(n=41)与研究组(n=45)。对照组采用谷维素片口服,1~3片/次,3次/d。研究组采用戊酸雌二醇片口服,1片/次,1次/d,2组疗程均24周。比较两组围绝经期症状Kupperma评分、同时检测性激素[雌二醇、卵泡刺激素(FSH)、黄体生成素(LH)]水平与血清SCC-Ag、MMP-9水平及不良反应发生情况。结果治疗后24周,研究组围绝经期症状Kupperma评分低于治疗前,差异有统计学意义(P<0.05),而对照组治疗前后比较,差异无统计学意义(P>0.05);研究组治疗后围绝经期症状Kupperma评分为(14.52±4.55)分,低于对照组[(19.77±4.96)分],差异有统计学意义(P<0.05)。治疗后24周,研究组的雌二醇水平较治疗前升高,FSH、LH水平较治疗前降低,差异均有统计学意义(P<0.05),而对照组治疗前后比较,差异均无统计学意义(P>0.05);治疗后24周,研究组的雌二醇水平为(39.28±7.39)ng/L,高于对照组[(15.91±5.27)ng/L],FSH、LH水平分别为(34.18±7.59)、(20.29±6.02)U/L,均低于对照组[(58.72±13.16)、(32.93±6.25)U/L],差异均有统计学意义(P<0.05)。同组治疗前后、治疗后组间的血清SCC-Ag、MMP-9水平比较,各种不良反应发生率组间比较,差异均无统计学意义(P>0.05)。结论宫颈鳞癌术后HRT治疗能有效改善低雌激素引起的更年期综合征,调节性激素水平,且不影响血清SCC-Ag、MMP-9水平,未增加不良反应发生,安全性较好。

GPR120、SCC-Ag、PD-1在非小细胞肺癌中的表达及其与临床特征、预后的关系

目的:探究G蛋白耦联受体120(GPR120)、鳞状细胞癌抗原(SCC-Ag)、程序性死亡受体1(PD-1)在非小细胞肺癌中的表达及其与临床特征、预后的关系。方法:选取2018年1月1日—2019年12月31日新疆生产建设兵团第一师医院收治的经手术治疗的81例非小细胞肺癌患者。分析所有患者临床特征(性别、年龄、肿瘤直径、分化程度、临床分期、淋巴结转移、累及程度)及预后情况,检查所有患者癌组织、癌旁组织GPR120 mRNA、SCC-Ag、PD-1 mRNA。比较所有患者癌组织、癌旁组织GPR120 mRNA、SCC-Ag、PD-1 mRNA。比较不同临床特征患者癌组织GPR120 mRNA、SCC-Ag、PD-1mRNA。比较存活组及死亡组GPR120 mRNA、SCC-Ag、PD-1 mRNA。分析GPR120 mRNA与SCC-Ag、PD-1 mRNA的关系。分析GPR120 mRNA、SCC-Ag、PD-1 mRNA对患者预后的预测价值。结果:癌组织中的GPR120 mRNA、SCC-Ag、PD-1m RNA均高于癌旁组织,差异有统计学意义(P<0.05)。低分化、Ⅲ~Ⅳ期、有淋巴结转移、累计肌层患者癌组织GPR120m RNA、SCC-Ag、PD-1 mRNA均高于中高分化、Ⅰ~Ⅱ期、无淋巴结转移、未累计肌层患者,差异有统计学意义(P<0.05)。81例患者随访6个月,22例死亡,59例存活。死亡组GPR120 mRNA、SCC-Ag、PD-1 mRNA均明显高于存活组,差异有统计学意义(P<0.05)。Pearson结果显示,GPR120 mRNA与SCC-Ag呈正相关(r=0.368,P=0.001);GPR120 mRNA与PD-1 mRNA呈正相关(r=0.314,P=0.004);SCC-Ag与PD-1 mRNA呈正相关(r=0.295,P=0.007)。ROC曲线分析,三项联合诊断AUC值高于GPR120 mRNA、SCC-Ag、PD-1 mRNA单项诊断。结论:在非小细胞肺癌中GPR120、SCC-Ag、PD-1m RNA呈高表达状态,与患者分化程度、临床分期、淋巴结转移、累及程度相关,且与患者预后相关,三项联合检测对非小细胞肺癌患者预后存活、死亡的判断价值较高。